Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice.
Lemere
C A
CA
Department of Neurology, Harvard Medical School and Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA. lemere@cnd.bwh.harvard.edu
Maron
R
R
Spooner
E T
ET
Grenfell
T J
TJ
Mori
C
C
Desai
R
R
Hancock
W W
WW
Weiner
H L
HL
Selkoe
D J
DJ
D000281:Administration, Intranasal; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D016229:Amyloid beta-Peptides / Q000008:administration & dosage / Q000276:immunology* / Q000627:therapeutic use*; D016564:Amyloid beta-Protein Precursor / Q000235:genetics*; D000818:Animals; D000917:Antibody Formation; D001921:Brain / Q000473:pathology; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D058225:Plaque, Amyloid / Q000473:pathology
D016229:Amyloid beta-Peptides; D016564:Amyloid beta-Protein Precursor